Chokri Ben Lamine: No Routine VTE Prophylaxis for Chronically Bedridden Patients at Home
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Short answer (guideline-based):
No routine VTE prophylaxis for chronically bedridden patients at home.
Guideline Position
American College of Chest Physicians (CHEST Guidelines)
Do NOT recommend pharmacologic prophylaxis for:
- Chronically immobilized patients
- Nursing home residents
- Home-bound patients without acute illness
Rationale:
- Lower VTE incidence vs hospitalized patients
- Higher bleeding risk outweighs benefit
American Society of Hematology (ASH 2018/2021 VTE Guidelines)
Suggest against routine prophylaxis in:
- Long-term immobile patients at home
- Unless additional strong transient risk factors present
When to consider prophylaxis (exception cases)
Only if high-risk transient state, e.g.:
- Recent hospitalization (≤45–90 days)
- Active cancer (especially + chemo)
- Prior VTE
- Acute infection/inflammation
- Marked reduced mobility with additional risk (improve score high)
In such cases short-term prophylaxis may be considered (case-by-case)
Extended prophylaxis trials (important nuance)
- MAGELLAN trial
- APEX trial
- MARINER trial
Show benefit in selected high-risk recently hospitalized patients, not applicable to stable chronically bedridden home patients
Practical Hematology Take
Bedridden alone isn’t indication
Always balance:
VTE risk vs bleeding risk
Focus on:
- Hydration
- Mobilization if possible
- Reassess if clinical status changes
Key References
- Kahn SR et al. CHEST Guideline (2012, updated concepts)
- Spyropoulos AC et al., MARINER Trial (NEJM 2018)
- Cohen AT et al., MAGELLAN Trial (NEJM 2013)
One-line clinical answer
No routine pharmacologic VTE prophylaxis for chronically bedridden patients at home unless additional high-risk transient factors are present.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research